Rolofylline
Alternative Names: KF-15372; KW-3902; KW-3902 Injectable Emulsion; KW-3902IV; MK-7418Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Kyowa Hakko
- Developer Kyowa Hakko; Merck & Co
- Class Neuroprotectants; Small molecules; Xanthines
- Mechanism of Action Adenosine A1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute heart failure; Cognition disorders; Hypertension
Most Recent Events
- 02 Sep 2009 Final safety and efficacy data from the PROTECT-1 and PROTECT-2 trials in Acute heart failure presented at the Annual Congress of the European Society of Cardiology (ESC-2009)
- 30 Jun 2009 Discontinued - Phase-III for Acute heart failure in Canada (IV)
- 30 Jun 2009 Discontinued - Phase-III for Acute heart failure in European Union (IV)